Historically, treatment success in atopic dermatitis was measured by visible lesion clearance and acute flare management. This framework underweights what patients often experience as most burdensome: persistent itch, disrupted sleep, fatigue, and emotional distress. These concerns frequently persist even when objective severity measures improve, and their systematic underrepresentation in treatment planning contributes to a disconnect between clinical assessments and patient-perceived outcomes.1
When flares recur despite treatment, patients and clinicians alike may begin to accept residual disease activity as an expected feature of the condition rather than a treatment shortfall.2 Sustained disease control, by contrast, correlates with meaningful improvements in sleep, daily functioning, and work productivity. Realizing those gains requires treatment planning that integrates patient-reported outcomes alongside clinical measures, an approach that remains inconsistently applied in practice, despite growing recognition of its importance.1
The availability of targeted systemic therapies has broadened these discussions, but also surfaced persistent gaps. Access remains uneven: the cost of biologic agents and Janus kinase (JAK) inhibitors places them out of reach for many patients, particularly where insurance coverage is limited, and financial burden is a recognized driver of nonadherence and discontinuation.1 Therapeutic inertia compounds this problem, escalation is frequently delayed even when treatment goals are not being met, often due to uncertainty about newer agents or the absence of clear escalation protocols. Timely treatment optimization, supported by updated guidelines and decision-support tools, is a practical priority.1,3
Population-level gaps also warrant attention. Clinical trial populations have historically underrepresented nonwhite patients, limiting the generalizability of efficacy and safety data across groups with recognized differences in disease presentation and treatment response.4 Evidence gaps also persist in pediatric populations, although the therapeutic landscape continues to evolve, with an increasing number of targeted therapies becoming available for younger patients and expanding opportunities for individualized care.1,6 Broader inclusion in clinical research, alongside longitudinal registries capturing patient-reported and real-world outcomes, would strengthen the evidence base needed to individualize care across diverse populations.
Biologics including lebrikizumab have demonstrated sustained clinical responses over extended treatment periods, providing evidence that durable disease control is an attainable goal for many patients.5 Anchoring treatment decisions to patient-defined priorities from the outset, while accounting for access, adherence, and population-specific factors, offers the most complete framework for moving beyond episodic disease management toward consistent, long-term control.1
Take our atopic dermatitis quiz to see how your knowledge compares to your peers.
